“…28.12b ) which was presented at the SABCS but not shown in the Lancet publication. The nearly statistically breast recurrences (ipsilateral, regional, contralateral, and distant) [ 50 ]; ( c ) pre-pathology only TARGIT-A ipsilateral recurrences [ 51 ] signifi cant difference in overall breast recurrences in the two groups ( p = 0.053) is a reason for concern, especially since the breast cancer deaths are already, even at 29 months median follow-up, higher with TARGIT (20 deaths, 2.6 %) than with EBRT (16 deaths, 1.9 %),…”